Charles River names president/COO; CRISPR chief scientific officer steps down

In This List

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

15 Feb, 2018 | 11:31

Author Muhammad Ahmer Gul Khan
Theme Healthcare & Pharmaceuticals

S&P Global Market Intelligence presents a weekly rundown of recent executive changes at pharmaceutical, biotech, and life sciences companies.

* Charles River Laboratories International Inc. appointed Davide Molho its president and COO.

* Bill Lundberg is stepping down as CRISPR Therapeutics AG's chief scientific officer and will transition to the role of senior adviser to the company.

* Acceleron Pharma Inc. appointed Sujay Kango its chief commercial officer.

* Axovant Sciences Ltd. CEO David Hung resigned. He is replaced by Pavan Cheruvu. Additionally, President and COO Marion McCourt resigned from the company to pursue another opportunity.

* Alkermes plc said Shane Cooke will retire as president and will join the company's board, effective March 30.

* Bluebird Bio Inc. named Alison Finger to be the company's chief commercial officer. Finger had been senior vice president of marketing and product launch at the company since August 2015.

* UroGen Pharma Ltd. appointed Stephen Mullennix its COO. Mullennix previously served as the CFO and senior vice president of operations for SolarReserve LLC, a power company.

* Bruce Cousins stepped down as CFO and executive vice president of Arbutus Biopharma Corp. The company's vice president of finance Koert VandenEnden will serve as interim CFO.

* Ashok Kumar Jindal resigned as the CFO and compliance officer of Parabolic Drugs Ltd.

* Arcturus Therapeutics Ltd. said Padmanabh Chivukula resigned as the company's chief scientific officer, COO and as a member of its board.

* CureDM Group CEO and board member Loraine Upham was appointed COO of Boston Therapeutics Inc.

* Ardelyx Inc. said Jeremy Caldwell will be stepping down as the chief scientific officer of the company Feb. 16. Caldwell is leaving to pursue a CEO role in a biotech startup company.

* CASI Pharmaceuticals Inc. appointed Wei-Wu He the company's executive chairman. He is currently chairman of the company's board.

* Actinium Pharmaceuticals Inc. appointed Anil Kapur chief commercial officer.

* Jennifer Bath will join ImmunoPrecise Antibodies Ltd. as president and CEO, effective Feb. 21.